ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target ...
The Brighterside of News on MSN52m
Natural dietary supplement can successfully treat Alzheimer's disease
A groundbreaking study by researchers from the University of Delaware College of Health Sciences and the National Institute ...